10x Genomics posts Q3 2026 results, launches Atera and lifts full‑year revenue outlook
10x Genomics reported third‑quarter 2026 revenue of $150.7 million, a 1% year‑over‑year increase, and an operating loss of $16.1 million. The company began commercial shipments of its new Atera instrument and introduced the Sentira cloud analysis platform. Management raised full‑year 2026 revenue guidance to $625 million‑$635 million, up from the prior $610 million‑$630 million range.
Why it matters
The raised revenue guidance expands the growth outlook for investors, while the Atera launch signals a shift toward higher‑margin consumables that could improve future profitability, as noted by the CEO. The higher gross margin of 75% this quarter reflects the early instrument mix but is expected to compress in Q4 as Atera shipments increase.
Key facts
- 1Revenue was $150.7 million for the quarter, up 1% YoY. prnewswire.com
- 2Operating loss was $16.1 million, compared with $32.2 million a year earlier. prnewswire.com
- 3Gross margin was 75% for the quarter, up from 67% a year earlier. prnewswire.com
- 4Cash and cash equivalents and marketable securities totaled $575.7 million as of September 30, 2026. sec.gov
- 5Full‑year 2026 revenue guidance was raised to $625 million‑$635 million, from $610 million‑$630 million. prnewswire.com
- 6The company began global commercial shipments of the Atera instrument and launched the Sentira cloud platform. sec.gov
Summary written by AlphAI AI Desk from 11 of 11 sources. Not investment advice. Figures are as stated by the linked sources.